PME Signs Research Collaboration Agreement with Mayo Clinic

3 June 2021; Company Announcement - Mayo Clinic Research Collaboration Agreement - Acrobat pdf 125k Highlights PME signs multi-year research collaboration agreement with Mayo Clinic Mayo Clinic to leverage the capabilities of the Visage AI Accelerator platform Collaboration to facilitate artificial intelligence (AI) research and development with a view to product commercialisation Builds on existing Mayo Clinic Visage 7 Viewer agreement Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly owned U.S. subsidiary, Visage Imaging, Inc., has signed a multi-year research collaboration agreement with Mayo Clinic. The agreement will serve as the framework for collaboration between the two parties to facilitate development and commercialisation in the field of AI leveraging the Visage AI Accelerator platform. “Our AI Accelerator program was designed to closely align Visage’s engineering and product development capability with clinical research partners such as Mayo Clinic who have a depth of clinical knowledge and extensive research expertise,” said Malte Westerhoff, PhD, Visage Imaging Global CTO. “It provides a unique set of tools for data de-identification, collection, curation, analysis and ‘path-to-production’ in research projects bringing the efficiency and speed of Visage technology to research, resulting in a unified link between the two domains.” Dr Westerhoff continued, “We see AI playing a significant role in healthcare particularly in our field of imaging IT. We have optimized our Visage 7 platform for AI enabling both our own, as well as third-party algorithms to be seamlessly integrated into the clinician’s desktop. We see this research collaboration agreement with Mayo Clinic as another significant piece of our AI strategy, one that has the potential to develop innovative AI solutions that meet well defined clinical goals and ultimately lead to better patient outcomes.”

PME Receives FDA Clearance for Breast Density Algorithm

2 February 2021; Company Announcement - FDA Breast Density 2 FEB 2021 - Acrobat pdf 109k Highlights First Artificial Intelligence (AI) algorithm developed by PME  Developed using PME’s unique end-to-end AI Accelerator solution  FDA clearance is in addition to previously received CE (Europe) and TGA (Australia) approvals  Paves the way for commercialization in North America, Europe and Australia  Opens up further research collabouration opportunities Leading health imaging company Pro Medicus Limited [ASX: PME] today announced that it has received FDA clearance for its Breast Density AI algorithm. This is in addition to previously receiving CE clearance (Europe) and TGA clearance (Australia) paving the way for the company to market the algorithm across all three jurisdictions. The Breast Density algorithm is intended for use with compatible full field digital and digital breast tomosynthesis systems. It assesses breast density from a mammography study and provides an ACR BI-RADS Atlas 5th Edition breast density category to aid radiologists in the assessment of breast tissue composition.  “We developed this algorithm using our own AI Accelerator platform which enabled us to significantly speed up every stage of the process from concept to FDA approval,” said Dr Sam Hupert, Pro Medicus CEO. “This not only provides us with a fast-track mechanism to develop our own algorithms in the future, it paves the way for further collaborations with the growing number of our research oriented clients.”

PME Signs Research Collaboration Agreement with NYU Langone Health

11 September 2020; Company Announcement NYU Research Collaboration Sept 2020 - Acrobat pdf 114k Highlights PME signs multi-year Research Collaboration agreement with NYU Langone Health PME and NYU Langone Health to jointly develop next-generation enterprise imaging solutions PME to establish Research/R&D Hub in New York City New Hub to form the foundation for Visage research activities in the U.S. Significant investment in future PME products Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly- owned U.S. subsidiary, Visage Imaging, Inc., has signed a multi-year Research Collaboration agreement with NYU Langone Health (NYU Langone), one of the most highly regarded health systems in North America. Under the terms of the agreement, the two parties will work together to design and develop next-generation products for enterprise imaging in areas such as workflow optimization, integration with multi-vendor reporting platforms, as well as integration of artificial intelligence (AI) technology. NYU Langone will also become a member of the Visage AI Accelerator program. “This is a major milestone for our company,” said Dr Sam Hupert, Pro Medicus CEO. “We changed the paradigm of what a diagnostic imaging (PACS) product should be by natively integrating 3D and advanced visualisation into a single platform. We believe this, combined with our proprietary streaming platform, has given us an 18 to 24 month technology lead. We are now looking at what is next, what a system would look like in say 3 to 5 years, and are starting to do the research and development to make that a reality and then be the first to commercialise it.” In addition to working on-premise at NYU Langone, PME will establish its own R&D Hub in New York City to spearhead PME’s research and

PME Signs A$25M – 7 Year Contract with NYU Langone Health

11 September 2020; Company Announcement NYU Sept 2020 - Acrobat pdf 118k Highlights PME signs 7-year, A$25M deal with NYU Langone Health NYU Langone ranked in the 10 best hospitals by U.S. News & World Report 2020- 2021 Tier 1 academic institution which includes the renowned NYU Grossman School of Medicine Visage technology to be deployed throughout NYU’s imaging departments replacing systems from legacy vendors Extends PME’s footprint in the tier 1 U.S. academic hospital segment Transaction-based model with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned U.S. subsidiary, Visage Imaging, Inc., has signed a 7-year contract with NYU Langone Health (NYU Langone), one of the largest health systems in the state of New York and one of the most respected and innovative healthcare institutions in North America. The contract, based on a transaction-based licensing model, will see the company’s Visage 7 technology implemented across all of NYU Langone’s radiology and subspecialty imaging departments, including breast imaging, replacing all existing legacy PACS with a single centralized instance of the Visage 7 Enterprise Imaging Platform. The implementation will span 6 hospitals and numerous additional locations across the NYU Langone healthcare network. Planning for the rollout is to commence in Q2 FY21, with the first sites scheduled to go-live in Q3 FY21. “NYU Langone completed a thorough selection process that required the final round of vendors to perform extensive on-site pilots. This enabled NYU to assess the differences between systems and, importantly, do so in their production environment, which is the ultimate test of how a product will perform,” said Dr Sam Hupert, Pro Medicus CEO. “Winning this deal further validates our belief that we have a unique and highly differentiated

Dr Sam Hupert | CEO on Update

PME OB 16 Dec 19 - Acrobat pdf 415k 16 December 2019 Open Briefing interviewed Pro Medicus CEO, Dr Sam Hupert, where he discussed: AGM Commentary - ahead of budget year to date plus strong cash inflow post balance date Feedback from the recent RSNA conference in Chicago Market’s reaction to PME’s AI accelerator platform announced at last month’s AGM Visage’s new Breast Density Algorithm Competitive landscape – positioning of PME technology                

Pro Medicus to Showcase Visage AI Accelerator at RSNA 2019

28 November 2019; Company Announcement - Pro Medicus to Showcase Visage AI Accelerator at RSNA 2019 - Acrobat pdf 119k Highlights PME to showcase Visage AI Accelerator at the RSNA 2019 meeting in Chicago New semantic annotation functionality to optimise curation and building of new AI models Collaboration with the American College of Radiology (ACR) to integrate Visage semantic annotations with ACR AI-LABTM AI ecosystem for Visage and third-party algorithms Visage developed breast density classification algorithm to be demonstrated as WIP Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned U.S. subsidiary, Visage Imaging, Inc., will be showcasing the Visage AI Accelerator solution and the new Visage developed breast density classification algorithm (works-in-progress (WIP)) at the Radiological Society of North America (RSNA) conference, December 1-5, 2019. Visage AI Accelerator is a multi-faceted, end-to-end solution translating AI ‘from research to bedside’. The Visage AI Accelerator solution includes: the Visage 7 AI research server, as well specialised data curation and annotation tools including the new semantic annotation capability to bridge the entire spectrum from research to diagnostic use via a single, unified platform. Key to the accelerator solution is an open API that enables native integration of both Visage and third-party developed algorithms into the company’s flagship Visage 7 product. “Radiologists have told us they don’t want separate systems when it comes to AI, so we developed an open API that allows our customers to choose the algorithms that best suit their needs all fully integrated into the Visage 7 Enterprise Imaging Platform. We see this as the foundation of our Visage AI Accelerator ecosystem and will be showing a number of third-party AI products seamlessly integrated into our platform at the RSNA,” said

PharmacySydney.com MJDHealthPharmacy.com
Go to Top